Dex-IN: Phase II started

Recro began the double-blind, placebo-controlled Phase II REC-14-013 trial to evaluate 50 Ug Dex-IN every 6 hours for 48 hours starting on post-operative day 1 in about 200-250 patients undergoing bun...